2013 American Transplant Congress
No Clinically Significant Effects of Calcium/ Calcitriol Supplementation on Loss of Bone Mass during the First Year after Renal Transplantation
Background: Bone disease is a well-known complication of renal transplantation, and vitamin D and calcium supplementation is commonly used to prevent loss of bone mass.…2013 American Transplant Congress
New Preperitoneal Surgical Approach for the Management of Vesicoureteral Anastomotic Stenosis or Reflux Following Renal Transplantation
IntroductionShort-or long-term ureteral complications such as vesicoureteral anastomotic stenosis or reflux occurring after renal transplantation remain a challenge. Even if pyeloureterostomy with the native ureter…2013 American Transplant Congress
Long Term (5-Year) Outcomes Using Subcutaneous Alemtuzumab for Induction in Highly-HLA-Sensitized (HS) Kidney Transplant Recipients
Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA
Introduction: Highly-HLA sensitized transplant recipients (HS) are at increased risk for AR/AMR after transplant. Subcutaneous alemtuzumab, a humanized anti-CD52 monoclonal antibody, appears both safe and…2013 American Transplant Congress
Cumulative Incidence and Factors Associated with Return to Active Status among Temporarily Inactive Obese Renal Transplant Candidates
Background: We studied the cumulative incidence and predictors of return to active status and transplant of obese kidney candidates designated “temporarily inactive” (status 7) due…2013 American Transplant Congress
Evaluation of Low-Dose Rituximab Treatment; the Incidence of Graft Rejection and Adverse Events in 313 Living Kidney Transplant Recipients
Urology, 8-1 Kawada-Cho, Shinjuku-ku, TOKYO, Japan
Background: In our department, 313 recipients underwent transplantations using a low-dose (150 mg/m2) rituximab protocol between 2005 and 2012. After the introductory period for this…2013 American Transplant Congress
Prevention of Cytomegalovirus with Valganciclovir 450mg Daily vs. 900mg Daily in Intermediate Risk Renal Transplant Recipients (D-/R+); a Multicenter Safety and Efficacy Evaluation
Multicenter CMV Pharmacists Collaborative Study Group, Boston
Cytomegalovirus (CMV) in renal transplant recipients (RTR) is associated with a high degree of morbidity. Current practice guidelines recommend CMV prophylaxis for 3-6 months with…2013 American Transplant Congress
Pretransplant CD8+CD28-NKG2D+ Memory T Cells and Third Party Cellular Alloreactivity as a Predictor of Posttransplant Acute Cellular Rejection
Background: Cellular alloreactivity is prevalent in patients prior to transplantation. A previous retrospective study showed that high cellular alloreactivity to a panel of third party…2013 American Transplant Congress
Fine Needle Aspiration Cytology and Detection of Lymphocyte Subsets in Kidney Transplant Patients Receiving Induction with Basiliximab or Thymoglobulin: Impact on Kidney Function
Induction therapy with basiliximab or thymoglobulin after kidney transplantation modifies the expression of lymphocyte subsets, including the Treg cells (CD127lowCD25high). Though this may influence the…2013 American Transplant Congress
Characteristics and Outcomes of Resistant Cytomegalovirus (CMV) Disease in Solid Organ Transplant (SOT) Patients
Objective: We assessed the characteristics and outcomes of genotype-proven resistant CMV after SOT.Methods : The SOT database was reviewed during 2001-2012 to identify patients with…2013 American Transplant Congress
Clinical Outcome of Living Donor Liver Transplantation in Patient with Hepatocellular Carcinoma and Impact to the Various Criteria
Surgery, Seoul St.Mary's Hospital, Catholic University of Korea, Seoul, Republic of Korea
Purpose: Liver transplantation (LT) as treatment for hepatocellular carcinoma (HCC) is known to be the best therapeutic option. To obtain good result, it is important…
- « Previous Page
- 1
- …
- 156
- 157
- 158
- 159
- 160
- …
- 178
- Next Page »